Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Ironwood Pharmaceuticals, Inc. is not very popular among insiders. Ironwood Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery...
IRWD Fundamental Data by TradingView

News

FY2024 EPS Estimates for Ironwood Pharmaceuticals, Inc. Cut by Zacks Research (NASDAQ:IRWD)
FY2024 EPS Estimates for Ironwood Pharmaceuticals, Inc. Cut by Zacks Research (NASDAQ:IRWD)

Zolmax Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research lowered their FY2024 EPS estimates for Ironwood Pharmaceuticals in a research note issued on...\n more…

Equities Analysts Offer Predictions for Ironwood Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:IRWD)
Equities Analysts Offer Predictions for Ironwood Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:IRWD)

Ticker Report Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research report issued on Monday...\n more…

Research Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:IRWD)
Research Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:IRWD)

Zolmax Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Stock analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Ironwood Pharmaceuticals in a research...\n more…

LSV Asset Management Sells 79,500 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
LSV Asset Management Sells 79,500 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Zolmax LSV Asset Management lowered its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 1.3% during the 2nd quarter, according to the company in its most recent disclosure with the...\n more…

Gallacher Capital Management LLC Buys 12,584 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Gallacher Capital Management LLC Buys 12,584 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Ticker Report Gallacher Capital Management LLC lifted its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 72.4% in the 2nd quarter, according to the company in its most recent filing with...\n more…

Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded by Leerink Partnrs to "Hold"
Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded by Leerink Partnrs to "Hold"

Ticker Report Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD - Free Report) to a hold rating in a research report sent to investors on Monday, Zacks.com reports. Leerink Partnrs also...\n more…